11.59 -0.04 (-0.34%)
Pre-Market: 4:23AM EDT
|Bid||0.00 x 1800|
|Ask||0.00 x 2900|
|Day's Range||11.32 - 11.78|
|52 Week Range||11.26 - 25.96|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.67|
Stocks in Warren Buffett's Berkshire Hathaway portfolio fell Friday. Among Buffett's holdings identified in Berkshire Hathaway's latest Securities and Exchange Commission filing, 11 rose while 35 fell.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Copaxone’s revenue erosionOn its first-quarter earnings conference call, Teva Pharmaceutical (TEVA) reaffirmed its 2019 global sales guidance of $1.30 billion for its
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Ajovy’s market expansion strategyOn April 2, Teva Pharmaceutical (TEVA) issued a press release announcing the European Union’s approval of its monthly and quarterly dosages
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Teva’s performanceIn the first quarter, Teva Pharmaceutical (TEVA) reported revenue of $4.29 billion, a YoY (year-over-year) fall of 15.20% and $89.76 million lower than the
The prices of generic drugs across the universe of pharmaceutical companies appeared to stabilize in the first quarter — shucking off years of broad decline, Wall Street analysts say.
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)EPS and EBITDA guidanceIn its first-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) reiterated its non-GAAP (generally accepted accounting principles) EPS
Teva or Endo: Which Is the Better Pick in May?Share price movementsOn May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close, 12.89% lower than its 52-week low of $14.04, and 52.89% lower than its 52-week
Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.
Shares of Mylan N.V. sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status. Mylan's long-term issuer default rating at Fitch is BBB-, the lowest investment-grade rating. Fitch said the revised outlook reflects its expectation that gross leverage may remain elevated over the near term because of slower-than-expected revenue growth, cash generation and debt reduction. Fitch's rating and outlook is similar to S&P Global Ratings' BBB- rating with a negative outlook, while Moody's Investors Service has a Baa3 rating--one notch above "junk"--with a stable outlook. Generic drug maker stocks have been under pressure in recent weeks, and took another header on Monday after more than 40 state attorneys general filed suit against 20 makers of generic medications, alleging a conspiracy to artificially inflate prices and reduce competition. Shares of fellow generic drug maker Teva Pharmaceutical Industries Ltd. slid 6.1% in morning trade to a 1 1/2-year low. Year to date, Mylan's stock has tumbled 27.6% and Teva shares have plunged 26.2%, while the SPDR Health Care Select Sector ETF has gained 1.3% and the S&P 500 has tacked on 13.3%.
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares were rocked this week after 44 different states filed a lawsuit against the company alleging Teva was among 20 different companies that conspired to manipulate and inflate drug prices. On Tuesday morning, Benzinga Pro subscribers received several options alerts related to Teva. The first trader purchased 1,521 call options at a $12.5 strike price that expire on Jan. 17, 2020.
NEW YORK , May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teva Pharmaceuticals Industries Limited ("Teva" ...
Shares of Teva Pharmaceutical crashed to an 18-month low Monday after 44 states filed a lawsuit outlining an alleged price-fixing scheme for generic drugs among pharmaceutical companies.
Stocks took a beating thanks to China trade worries, with Boeing falling on further 737 MAX concerns and Teva Pharmaceutical and other generic-drug makers tumbling after getting sued.
Stocks that moved substantially or traded heavily on Monday: Teva Pharmaceuticals Ltd., down $2.13 to $12.23 The company allegedly conspired with other generic drugmakers to inflate and manipulate prices, ...
Stocks ended sharply lower Monday after China said it would increase tariffs on as much as $60 billion worth of U.S. imports to as high as 25%. shares tumbled 5% as investors worried about the impact of China's tariffs on the tech giant. Stocks fell sharply Monday, logging their steepest declines since early January after China said it would increase tariffs on as much as $60 billion worth of U.S. imports to as high as 25% in response to last week's collapse of trade talks between the world's two largest economies.
The market's sidestepped a big market selloff last Monday. This Monday, it wasn't so fortunate. At its lows, the Russell 2000 and Nasdaq were both down more than 3%, although some positive trade talk did give stocks an afternoon lift. Let's look at a few names that are in the headlines, giving us some juicy top stock trades to watch. Top Stock Trades for Tomorrow 1: Amazon Click to EnlargeAmazon (NASDAQ:AMZN) falling to and testing the 50-day moving average will almost surely attract some dip buyers. The stock is $130 off its recent highs and testing a key moving average. Many popular names are getting hit right now.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI might miss my chance in AMZN by waiting, but I'm looking for a slightly deeper correction. If we can get a pullback in Amazon down to the 200-day moving average near $1,755, shares will be down just over 10% from the recent highs. * 6 Trade War Stocks With a Lot of Risk It'll also be bumping into prior resistance, which will hopefully act as support. Between this and the 200-day moving average, AMZN stock should at least give us a good bounce should it fall that far. Top Stock Trades for Tomorrow 2: Uber Click to EnlargeFriday was an ugly day one for Uber (NYSE:UBER) and day two isn't shaping up much better, with shares falling another 11%. I don't know where or when Uber will bottom, but it feels like more selling is on the horizon. If the market selloff continues, don't look to Uber for safety.While Lyft (NASDAQ:LYFT) had a much better day-one open than Uber, it too has been a train wreck. Shares are now below $50 and down more than 45% from its opening print.If you're thinking about investing in Uber for the next five to 10 years, that's one thing, (I don't know if it's a good price or not). But if you're looking to trade this one, I would avoid it for now. The stock is too wild and the risk can't be defined yet. Top Stock Trades for Tomorrow 3: Teva Click to EnlargeSomeone needed to do worse than Uber on Monday and Teva Pharmaceutical (NYSE:TEVA) stepped up to the plate with the stock down about 15% on price fixing allegations.The 200-week moving average stymied any potential rally in the second half of 2018 and the 10-week moving average kept a lid on each potential rally in 2019 too. It has continued to squeeze Teva lower and has kept the stock in a nasty downtrend.Now what? A rally back to prior downtrend support may be in the cards, but it's also likely that this level acts as resistance moving forward. Teva may be setting up for a retest of its lows near $11.50. It may find buyers there, at least in the short term. Top Stock Trades for Tomorrow 4: Zscaler Click to EnlargeOver the weekend, I was looking for stocks that displayed strength in the previous week amid heightened volatility and increased selling pressure. Zscaler (NASDAQ:ZS) was one of them, even though the stock is down almost 5% on Monday.That nixed the breakout over $72.50, but with the markets down so heavily on the day, it's no surprise. I want to see this one pullback a little further into that 20-day/50-day moving average conflux, as well as uptrend support in the same area.If it does and the pullback holds, ZS is a buy in my mind for the short-term. A break of $65 spells trouble. Top Stock Trades for Tomorrow 5: S&P 500 ETF Click to EnlargeThe 50-day temporarily broke but ultimately held for the SPDR S&P 500 ETF (NYSEARCA:SPY) over prior two sessions before we got to Monday. To start the week though, the SPY gapped below the 50-day and opened near Friday's lows, where it promptly failed and moved even lower.Leading up to the break, the 20-day was acting as resistance, a clue that the trend had changed and investors were positioning themselves in a less-aggressive manner. I would look for a bit more downside now. At $275 we have the 200-day and around $277 was a big resistance level in the fourth quarter. * 10 Stocks That Could Squeeze Short Sellers, Including CGC If those levels act as support, we could get a decent bounce -- perhaps back up to the 50-day -- as we continue to digest trade-war headlines.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AMZN. Compare Brokers The post 5 Top Stock Trades for Tuesday: Amazon, Teva, S&P 500 appeared first on InvestorPlace.
Teva stock, already down 20% year to date, was on pace to set a 52-week low on Monday, a day after 44 states, led by Connecticut, announced an antitrust lawsuit against 20 generic-drug manufacturers
Pharmaceutical company Teva is accused of inflating drug prices. The stock plummeting after 44 states accused Teva and 19 other drug companies of driving up the market prices for generic drugs to avoid competition. Yahoo Finance's Seana Smith and Jared Blikre discuss.